TEHRAN – The European Society for Blood and Marrow Transplantation (EBMT) granted membership to Motamed Cancer Institute on March 11.

The EBMT is a non-profit medical and scientific organization established in 1974 that hosts a unique patient registry providing a pool of data to perform studies and assess new trends.

It aims to be the connection between patients, researchers, and other stakeholders to anticipate the future of cellular and stem cell-based therapies.

The community of healthcare professionals is focused on innovation, research, and the advancement of these fields to save and improve the lives of patients with blood-related disorders.

The first bone marrow transplant in Iran was performed in the Iranian year 1396 (March 2017-2018).

In February, according to an assessment of the Ministry of Health, Treatment, and Medical Education, Motamed Cancer Institute was ranked first among all research centers in the field of cancer, both clinical and biomedical, throughout the country.

The institute also ranked second among all clinical research centers with independent funding and experience of more than 10 years, regardless of the subject of activity, IRNA reported.

Also, among the total of 833 private and government research centers under the Ministry of Health, the breast cancer research center of the Institute has been evaluated as one of the top 10 centers.

Various indicators such as effectiveness, patents, interdisciplinary theses, five-year H index, total five-year documents, articles with international cooperation, articles published in the top 25% of publications, and research output have been among the indices of the assessment.

***EBMT membership

The EBMT has more than 7,200 members in over 70 countries.

Members contribute to and benefit from the collective knowledge that the EBMT has accumulated within the EBMT Registry.

The EBMT Registry is the backbone of the EBMT’s research and educational activities.

The main purpose of the Registry is to provide a pool of data to EBMT members to perform studies and assess new trends in BMT, gene therapy and cellular therapy.

MT/MG